home *** CD-ROM | disk | FTP | other *** search
Text File | 1992-11-17 | 48.9 KB | 1,501 lines |
- Newsgroups: sci.med
- Path: sparky!uunet!omen!caf
- From: caf@omen.UUCP (Chuck Forsberg)
- Subject: Adiposity 101 3/3
- Archive-Name: adiposity.101/part03
- Organization: Omen Technology Inc
- Date: Tue, 17 Nov 1992 13:41:38 GMT
- Message-ID: <1992Nov17.134138.9464@omen.UUCP>
- Submitted-By: caf@omen
- Lines: 1489
-
- ---- Cut Here and feed the following to sh ----
- #!/bin/sh
- # this is fat.03 (part 3 of adiposity.101)
- # do not concatenate these parts, unpack them in order with /bin/sh
- # file adiposity.101 continued
- #
- if test ! -r _shar_seq_.tmp; then
- echo 'Please unpack part 1 first!'
- exit 1
- fi
- (read Scheck
- if test "$Scheck" != 3; then
- echo Please unpack part "$Scheck" next!
- exit 1
- else
- exit 0
- fi
- ) < _shar_seq_.tmp || exit 1
- if test ! -f _shar_wnt_.tmp; then
- echo 'x - still skipping adiposity.101'
- else
- echo 'x - continuing file adiposity.101'
- sed 's/^X//' << 'SHAR_EOF' >> 'adiposity.101' &&
- X
- X
- X
- Committees reviewing the use of human subjects in these
- experiments should not assume that they are ethically
- uncomplicated. The low probability that information of
- therapeutic value will result from such a study should weigh
- heavily in any deliberation on whether to authorize it."
- X
- "I can see little reason for intake restriction to receive
- continued support, either as a subject of research or as an
- accepted therapy for obesity. Bloodletting as a therapy for
- pneumonia was abandoned about a century before penicillin
- was discovered. It required a modicum of courage and good
- sense on the part of practitioners who turned away from the
- practice, but there is no reason to believe their patients
- suffered from this lack of therapy."
- X
- "A survey of studies published 1977-1986 and reporting on
- dietary or behavioral treatment of obesity reveals that the
- maximum percentage of body weight lost is, on average, 8.5
- percent - no different from the value, 8.9% in similar
- studies from 1966-1976, as reviewed by Wing and Jeffery."
- X
- "The goals and research methods of studies on dietary
- treatments for obesity are overdue for ethical as well as
- scientific reevaluation. The same may be said for the
- numerous programs providing such treatment outside the
- context of research."
- X
- A final footnote on combining diets and exercise. A Harvard
- Health letter compared results of 1982 and 1991 surveys of
- doctors' lifestyles. Since 1982 the doctors reduced their
- consumption of red meat, fat, and cholesterol. They
- increased their dietary fiber and exercised more.
- Unfortunately, the increased attention to diet and exercise
- did not produce leaner bodies; the proportion reporting
- weight problems increased from 29 to 39 per cent.
- X
- While diet evangelists continually assert that new wrinkles
- in 60+ year old treatments are improving weight loss
- outcomes, the long term success rate of even the best
- available weight loss programs using diet, exercise, and
- behavior modification remains less than five per cent. (NIH
- conference on voluntary weight loss, Mar 30-Apr 1 1992)
- X
- X
- 7. FLAWED RESEARCH
- X
- The quality of diet research and media coverage on the
- problem of adiposity often leaves much to be desired. The
- vast majority of this research is so sloppy it would never
- be accepted by the FDA as proof of an ethical drug's
- efficacy.
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 45 -
- X
- X
- X
- The reader should beware of two common flaws in popular
- obesity studies:
- X
- 7.1 Correlation .vs. Cause and Effect
- X
- A typical correlation study might show that joggers are
- thinner than couch potatoes. This is a *correlation*. Such
- data are generally accepted as proof that obesity is caused
- by lack of exercise, with the implication that fat couch
- potatoes will become thin if only they get off their lazy
- butts and exercise.
- X
- What is the error in drawing such a conclusion? The error
- is the unstated assumption that the correlation proves a
- particular cause and effect. In fact, other cause and
- effect relationships may be involved. Conventional wisdom
- concludes: Lack of exercise causes obesity. The other
- explanation for the observed correlation is: Obesity and
- associated impaired muscle development makes sports
- activities unpleasant and frustrating if not impossible.
- X
- "While the link between exercise and health in some large
- epidemologic studies seems powerful, intervention and
- outcome studies suggest a more qualified correlation. ...
- Yet "we still have no clinical trial to demonstrate that
- increasing activity in a group of sedentary people reduces
- the rate of disease vs sedentary controls," says William
- Haskell, PhD, also a member of the Stanford faculty." (JAMA
- June 12, 1991)
- X
- Correlation studies that draw conclusions or make
- recommendations without properly evaluating alternative
- models of causality are fundamentally flawed and must be
- treated with suspicion.
- X
- 7.2 Flawed Sample Selection/Distribution
- X
- Non-random selection or partitioning of the sample
- population flaws many studies that otherwise appear to be
- well designed.
- X
- One cannot allow subjects to select which experimental group
- they will join because the selection process may be stronger
- than the experiment. News media might not understand the
- implications, but the study will be flawed.
- X
- For example, a study on the mortality effects of obesity was
- based on patients who had repeatedly lost and regained
- weight, compared to lean individuals. Was the higher
- mortality caused by obesity, by the dieting, or did diet
- cycling cause both?
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 46 -
- X
- X
- X
- Diet studies typically exclude dropouts from their data.
- This is not acceptable in weight loss research because
- dropouts generally have lower weight loss and greater weight
- regain. Excluding even a few such data points distorts the
- experiment because the variability between subjects is much
- greater than the average weight loss (SD >> M).
- X
- Studies comparing the relative success of alternative
- treatments rarely assign subjects to the alternatives at
- random. The factors that determined sample selection and
- partitioning may be more important than the alleged
- independent variable.
- X
- X
- 8. TRUTH IN RESEARCH PAPERS
- X
- The honesty and integrity in life sciences research has
- increasingly come under question.
- X
- We understand the pressure on a corporation or trade
- institute to manage information about the safety and
- efficacy of its products and services. Such pressures are
- not limited to the corporate sector. Weight loss
- researchers live by the "publish or perish" syndrome.
- Exaggeration of weak results is sometimes a necessary
- expedient to secure continuing research funding. "When all
- you have is a hammer, everything starts to look like a nail"
- applies to research projects.
- X
- "It is seldom necessary to list individual results in a
- paper. Data can usually be summarized by a measure of
- location and a measure of dispersion. A common practice is
- to list the arithmetic mean, standard deviation (S.D.) and
- the number of observations (n) used to estimate these
- statistics. If only a few observations are available the
- dispersion is better indicated by the range. If the
- distribution is significantly skewed [not a "normal
- distribution"] both the median [50th percentile] and range
- [minimum and maximum] should be cited." (Journal of
- Endochrinology, 1992)
- X
- How can one spot "fudged" research? One way is to look at
- the way data is presented. If mean (average) values for the
- experimental groups are presented, check the standard
- deviation values. The standard deviation must be small
- compared to the reported differences between groups. If the
- standard deviation is comparable to the differences between
- groups, the data can not be used to analyize individuals.
- X
- Diet evangelists dismiss or downplay the importance of
- genetics and other inborn differences affecting the
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 47 -
- X
- X
- X
- development of obesity. Large standard deviations highlight
- the biological differences between fat and thin people. If
- the standard deviation is not disclosed, the researcher is
- hiding something from the reader.
- X
- #Diet studies typically exclude dropouts from their data.
- This is not valid in weight loss research because dropouts
- generally have lower weight loss and greater weight regain.
- Excluding even a few such data points generates a false
- positive finding because the variability between subjects is
- much greater than the average weight loss (SD >> M). Goal
- directed programs and programs that insist that subjects
- will succeed if only they follow the regimen provoke highly
- skewed dropouts.
- X
- #Weight loss studies often present the average weight loss
- of a subset of the experimental cohort. Most such samples
- are not representative of the overweight population, yet
- vital questions of relevance to the overweight population
- are rarely addressed. What portion of the overweight
- population was not eligible for or excluded from the
- program, thus introducing selection bias? (Williamson &
- Levy, Int J of Obesity, 1988)
- X
- #Long term studies pose further problems for studies without
- a non-dieting control group. Williamson and Levy analyzed
- weights recorded for medical purposes at two clinic visits
- separated by intervals of 1 to 5 years. These were 332
- adult patients who were initially at least 20 per cent
- overweight. The 59 patients measured over a 5 year interval
- showed an "apparent weight loss" for 31 per cent of this
- group with a mean decrease of 7.3 kg. This long term random
- weight loss is comparable to the positive results reported
- by some diet and behavior programs.
- X
- Unless a significant loss beyond baseline is demonstrated by
- weight loss studies and programs, no effect should be
- attributed to the program. Control groups that account for
- random weight changes (mostly from unsupervised dieting) are
- essential in studying the long-term maintenance of weight
- loss.
- X
- Any study that takes weight loss as a goal should include
- the following information:
- X
- X + Weight, height, and Body Mass Index (BMI) for subjects
- X at entry, then weight and BMI at each follow-up time.
- X
- X + Number and size of fat cells before slimming, after
- X slimming, and after weight regain.
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 48 -
- X
- X
- X
- X + When expressed as means, these values should be
- X accompanied by the standard deviation, not the standard
- X error.
- X
- X + Data for males and females should always be separated.
- X
- X + If the study contains more than one experimental group
- X and/or a control group, subjects must be randomly
- X assigned to each group.
- X
- X + If the study contains more than one experimental group
- X and/or a control group, the data should be presented
- X for each group.
- X
- X + Studies with 50 or fewer subjects should present
- X individual data.
- X
- X + Data should include followup for a minimum of three
- X years after treatment ends.
- X
- X + If there are drop-outs, the remaining number of
- X subjects should be recalculated and reported along with
- X the mean weight at follow-up. Almost all drop-outs
- X regain their weight loss or more, and must be
- X calculated this way.
- X
- X + Weight loss studies should report the number and size
- X of adipose cells before slimming, after slimming, and
- X after weight regain.
- (Based on recommendations by by William Bennett, Harvard
- Medical School Health Letter)
- X
- X
- 9. MEDIA DISTORTION
- X
- Heavy advertising, a "thin is in" ethic, media preoccupation
- with unusually obese individuals, and built-in repeat
- business have bloated the diet industry into a 33 billion
- dollar a year enterprise.
- X
- As Professor Garner's 1990 testimony before the House of
- Representatives indicated, false advertising is rampant in
- the diet industry. While an individual deceptive diet ad
- may not be too misleading to the public at large, the
- collective effect of such deception (Nazi Big Lie effect)
- creates great damage.
- X
- Weight Watchers, Nutri/Systems and other diet promoters
- refuse to divulge their long term weight loss data.
- X
- Misleading advertising is, unfortunately, normal for the
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 49 -
- X
- X
- X
- diet industry. The majority of diet food products tested
- for the New York state Consumer Protection Board contained
- more calories than listed on their package labels. 80
- percent of the diet food products tested exceeded claimed
- calories, some by as much as 73 calories per serving.
- X
- X
- 10. NEW TECHNOLOGY
- X
- 10.1 STIMULATION OF THERMOGENISIS
- X
- Thermogenisis refers to the generation of body heat in
- muscle and brown adipose tissue (BAT).4 Lean subjects
- increase thermogenisis in response to meals, exercise, and
- cold weather. Obese subjects show less of each of these
- responses than lean subjects. Obese subjects are less
- tolerant to long term cold exposure because of their
- inferior thermogenisis capability.
- X
- These facts have prompted many investigations into the
- possibility of reducing obesity by increasing thermogenisis
- in the obese.
- X
- In their book "Life Extension Weight Loss", Pearson and Shaw
- suggest thermogenisis enhancing drugs and cold exposure as
- ways to burn up fat.
- X
- Caffeine, ephedrine, nicotine and other materials have been
- shown to increase metabolism in humans. Aspirin increases
- the thermogenic effectiveness of ephedrine in obese but not
- lean women. Some are associated with weight loss during the
- treatment period. Common side effects of such treatment
- include high blood pressure and heart palpitations.
- X
- #Ephedrine quadrupled the weight loss of obese women whose
- metabolisms had been depressed by previous dieting.
- (International Journal of Obesity, 1987: 163-8)
- X
- A double-blind Danish study reported that ephedrine 20mg +
- caffeine 200mg administered three times daily dramatically
- increased fat loss and fat oxidation (see "fast fibres") and
- reduced loss of fat-free mass. Three of the 8 patients on
- E+C complained of insomnia, palpitations, and tremor,
- respectively. (Metabolism, 41;7 July 1992)
- X
- X
- __________
- X
- X 4. There is some controversy about the location of
- X thermogenisis in adults (BAT or muscle tissue).
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 50 -
- X
- X
- X
- Smokers gain weight when they quit smoking; their final
- weight averages the same as that of non smokers. This
- suggests nicotine reversibly depresses weight, 6 to 7 per
- cent according to University of Wisconsin researcher Richard
- Keesey. Nicotine reduces weight by increasing metabolism,
- not by reducing appetite or food intake. A growing number
- of young women have discovered this, and cigarette smoking
- is gaining popularity as a weight control measure.
- X
- Pearson and Shaw recommend nicotinic acid to increase
- thermogenisis and as a recreational drug.
- X
- A study of obese women on a swimming program suggests their
- heat loss to water had the opposite effect, increasing their
- fat stores. It's been reported that women gain 10 pounds in
- less than a week's time when they move to Alaska; they lose
- this weight when they move back to a warmer climate. #This
- weight gain may be the result of BAT lipogenesis.
- X
- It has been suggested that early exposure to cold might
- promote adult leaness. (p. 75, Obesity and Leanness - Basic
- Aspects) Improvements in household heating in this century
- may account for an increase in obesity.
- X
- 10.2 GROWTH HORMONE TREATMENT
- X
- The pituitary gland releases Human Growth Hormone (HGH) in
- bursts, mostly during the early hours of sleep. Human
- Growth Hormone promotes muscle growth and fat loss. The
- obese produce much less HGH than normal.
- X
- Obesity is associated with reduced 24 hour integrated
- concentrations of growth hormone (IC-GH) and elevated
- concentrations of insulin (IC-I) compared to lean
- individuals. The difference in growth hormone levels is
- greatest in childhood. The difference in growth hormone
- between lean and obese children that IC-GH of obese children
- are typical of poorly growing children with classical
- growth hormone (GH) deficiency. In contrast to children
- with classical GH deficiency, obese children are generally
- normal or above average for height, growth rate, osseous
- maturation and IGF-1 levels.
- X
- A study reported in the Dec 3 1990 Wall Street Journal
- reported that short children treated with growth hormone
- lost a "drastic 76 per cent of body fat" while gaining as
- much as 25% lean body mass (compared to untreated controls).
- X
- Obese individuals normally release very little or no
- detectable HGH. Even under the most strenuous exercise,
- obese individuals release only a small fraction of the HGH
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 51 -
- X
- X
- X
- lean sedentary individuals release in normal sleep.
- X
- A study of lipid metabolism in lean and pre-obese swine
- (pigs of normal weight which will become fat) indicated low
- levels of growth hormone at least until sexual maturity, and
- an enhanced deposition of blood lipids as fat compared to
- lean subjects. (International Journal of Obesity 1990, 14,
- 21-29) This enhanced deposition is significant in two ways.
- First there is the direct accumulation of fat. Secondly
- this deposition of fat "short circuits" metabolism of blood
- lipids into cholesterol and steroid hormones. This theory
- helps explain why destruction of fat tissue allows animals
- to grow up with more muscle mass than identical but
- untreated controls.
- X
- In the future, high risk babies might be given lipid
- tolerance tests, and pre-obese individuals treated with HGH
- and DHEA to keep them from becoming fat.
- X
- In a recent study, administration of synthetic growth
- hormone to elderly male patients to normalize their low HGH
- levels resulted in significant muscle gain and fat loss.
- X
- A Dutch study 8 GH deficient patients reported that 6 months
- GH therapy increased lean body mass and decreased fat mass.
- The sense of well-being improved in most patients.
- Cholesterol levels decreased. (Clinical Endocrinology 1992
- 37, p. 79)
- X
- A study at St. Thomas' Hopsital in London found that
- patients with hypopituitarism have altered body composition
- and quality of life. In comparison with a matched control
- group such patients had considerably reduced lean body mass
- and increased fat mass and waist to hip ratio. A number
- were significantly depressed, sufficient to justify therapy.
- "We conclude that there is a morbid syndrome associated with
- growth hormone deficiency in adult life which responds
- dramatically to hormone replacement. To be effective this
- therapy has to be continued indefinitely."
- X
- Exogenous GH increases lean tissue and reduces body fat in
- obese women in the absence of significant energy
- restriction. (Hormone Research 1991, 19-24)
- X
- Obese men manifest fewer GH secretory bursts per 24 h and
- accelerated HGH disposal rates. (Journal of Clinical
- Endocrinology and Metabolism 72:1 p. 51)
- X
- X
- HGH may be useful in reducing diet-induced loss of lean
- tissue.
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 52 -
- X
- X
- X
- 10.2.1 Growth Hormone Stimulation HGH is expensive. An
- alternative to HGH injection is to stimulate the body to
- excrete HGH.
- X
- Pearson and Shaw recommend stimulation of human growth
- hormone (HGH) excretion with arginine amino acid supplements
- as a weight loss method. Unfortunately, the references
- given in their book indicate their recommended amino acid
- megadosage is still orders of magnitude too small to cause
- the obese to release detectable amounts of HGH.
- X
- The obese have a high threshold which must be surpassed by
- strenuous exercise (to the point of exhaustion) or
- "incredible" doses of amino acids (orders of magnitude more
- than even Pearson&Shaw recommend) before any stimulation of
- HGH release is noted. HGH levels achieved under these
- exceptional conditions are still only a fraction of what
- lean subjects spontaneously produce in their sleep.
- X
- Long term propranolol therapy increases body weight in heart
- attack patients (2P-14); this may modify some of Pearson and
- Shaw's recommendations.
- X
- "Chronic ingestion of L-dopa (an HGH releaser) leads to
- sustained but reversible weight loss in both lean and obese
- Zucker rats."
- X
- 10.3 DHEA TREATMENT
- X
- Dehydroepiandrostone (DHEA) reduces weight gain in the
- hypercorticosteronemic Zucker fatty rat, an animal of
- genetic obesity. Its chronic anti-obesity effect is thought
- to reflect a chronic antiglucocorticoid activity. (Int J of
- Obesity, 1992, 579-)
- X
- University of Wisconsin researchers treated normal and 19
- spontaneously obese dogs with DHEA. The normal weight dogs
- did not reduce weight or energy intake. Two-thirds of the
- obese dogs lost 20 percent of their excess body weight and
- dropped cholesterol levels by nearly 25 percent without
- reduction in food intake. (Int J of Obesity 1990, 14,95-
- 104)
- X
- The 1990 Journal of Nutrition reported that DHEA treatment
- reversed dietary induced obesity (from a mixture of corn oil
- and condensed milk) as well as genetically induced obesity
- (fa/fa rat).
- X
- In premenopausal obese women, DHEA levels are inversely
- proportional to BMI. Adipose cells remove DHEA from the
- bloodstream; enhanced removal of DHEA in severely obese may
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 53 -
- X
- X
- X
- account for their impaired sensitivity to caloric
- restriction. (Metabolism, Feb 91, p 187)
- X
- Pearson & Shaw claim the "DHEA" sold by health food stores
- is bogus. The author of "The Vitamin Bible" reports
- successful personal weight loss with DHEA but gives no
- sources or details.
- X
- 10.4 RU-486 TREATMENT
- X
- RU-486 causes obese mice to lose weight by getting fat cells
- to generate heat rather than store fat. RU-486 also blocks
- the effects of glucocorticoids. Reportedly RU-486 can help
- cure Cushing's syndrome, a gland disorder characterized by
- obesity and hypertension. "Potentially the most potent
- anti-aging drug available." (Longevity, Jan 1991) The 1990
- American Journal of Physiology reported that RU-486
- effectively reversed the obesity of fa/fa rats.
- X
- A paper in the 1992 International Journal of Obesity reports
- that Norepinephrine (the neural transmitter, not the asthma
- drug) inhibits rat pre-adipocyte proliferation.
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 54 -
- X
- X
- X
- 10.5 CoPP TREATMENT
- X
- The 1990 Pharmacology reported that injections of cobalt-
- protoporphyrin completely reversed the obesity of Zucker
- fa/fa fatty rats to normal. Significantly, untreated rats
- that were fed the same amount of food as the CoPP treated
- rats for the first 42 days reverted to the same weight as
- untreated fatty rats by day 60. This indicates CoPP caused
- a long term reduction in the rats' set point.
- X
- #X#8O8##TILH#8OIi=L=;+;;=i;iX=88i88X#;XT;;8X;X)==;+;;=+++++++++++++++++++++++++
- #####+Li8i#)i);=+O+==;;;;+;+;+==I=L+=+I##;=8iO###8X;HiX888888;;+;;;;;;888888IL+
- ###O####)#8I#)####i#+;;;;i=8#8####O######II))######8)i;;=+;=+;+;+;;+;;=;;++I+++
- ###L###############TT:#X##X=##X#=#IO#OH##i#+=#8##+ ;=88I88+
- #########=####H#8I= ###T==######O8X###=OTH#X) 88+
- ####L#=####88##I+i ;###O#L8##L#T##8O#O8II;+ ;:+
- ##8#XH##########= =Xi#XO#=##O#=###)==#+: +:+
- ##I##8+#I######= ;=L#;I+T#i8O#;###H;I +
- #########L=###X ;##I##=#8#I8OT#+## ;+
- #######X#8#X##L :I8IL#+O+=#8X;#iX##X ::+
- #==T#8####L##++ ;L8I#I#IH###Xi;L8X8I ;+
- #####L#=;##H :#II8I8I*x#+##XO#;8# ;+
- ######88i#= ;=II8I8I8I+;+ ;: =; #IL
- #8#+#####8 :XXI8I8I8;i#;X8;8O: +; ;X#;8
- ####=O##8 :#XI8I8I88#H;8# 8=8Oi #8XT=
- ###=+88X: #XI8I8Ii 8=+HX=#X#OH+;# ;: ;+ ;+ ;=;##8;8
- ##8HO#= #XI8I8II8+XL) 88X+X=;+8;O;I+H;8 : ;: ;II;XX##X;8
- #I;== ,#X8HX8X**X*X*X 8 XI;==#;8;iO: L ;=XO=888X;L;Oi88888
- ##### =L###XXIiX+T X ;XI88;=;=;I: ;+ ;+H=ITiO8;+;IL;X8;i8;8;
- ####### ;X#I=#H=X;LI8;=;88i XX;88 :::;+;L;=X=T)T;+;=8;8888=+L=88
- ########## #X=#X=ILL#I#8;8L;=L+ + L+OI THO ;O +;8=;);=i X8L8;X8H= IL8
- #############X=#X=#IL#8###########THHX H;I+;O 8,8)=;iH+=L;T888+=Hi;8);8X;=X
- ##=8=i#=88+i;=L;I;IX)+=;8=)8iL8+;+;;O;#i;#XO;8X8;;;=O==I==H=LT=8=+;X+;H+===++;=
- X
- Typical CoPP treated (left) and untreated (right) Zucker
- fatty rats. Look at this from a distance to get the best
- effect. (B/W Xerographic photocopy of original color plate
- was scanned, converted to GIF format by XView, converted to
- ASCII with ASCGIF.)
- X
- 10.6 CIRCADIAN LIPOSTAT MANIPULATION
- X
- Obesity and type II diabetes may be the result of defective
- circadian [daily cycle] neuroendocrine rhythms.
- X
- #Albert Meier, professor of zoology at Louisiana State
- University, initiated a study of bromocriptine after 25
- years of research on animals' body rhythm biology during
- migration and hibernation. What he attempted to translate
- to humans was the finding that many animals reduce or
- increase their body fat without altering food intake or
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 55 -
- X
- X
- X
- activity levels. (Insight, Mar 26 1990)
- X
- Meier, Cincotta and Lovell have dramatically reduced body
- fat with oral bromocriptine taken orally at times calculated
- to reset circadian hormone rhythms to phase relationships
- that cause loss of body fat. Bromocriptine is a dopamine
- agonist used to suppress lactation and in treatment of
- Parkinson's disease.
- X
- "The phase of the prolactin rhythm differs in lean and fat
- sparrows, fish, rats, and humans. Daily injections of
- prolactin in animals at times when the daily peaks occur in
- the plasma of lean and fat animals produce the appropriate
- decrease or increase in fat stores within two weeks."
- X
- In early clinical trials, without food restriction, body fat
- was reduced equivalent to a 420 calorie VLCD, but without
- the loss of lean body mass caused by weight loss diets.
- Studies with Syrian hamsters investigating whole body
- protein turnover indicate this treatment enhances protein
- synthesis, redirecting anabolic activities from lipid to
- protein. Apparently the timed bromocriptine treatment
- alters the genetically controlled partitioning of nutrients
- described in "The response to long-term overfeeding in
- identical twins" discussed above.
- X
- In the second study reported in Experientia 48 (March 1992
- p. 248-), 15 diabetic subjects were given timed
- bromocriptine treatment. As with the non-diabetic subjects,
- all 15 diabetic subjects lost fat.5 Blood glucose dropped
- significantly. Oral hypoglycemic medication was was
- discontinued in 3 participants, and glucose levels remained
- near normal for at least two months after treatment. Doses
- of hypoglycemic drugs and insulin were reduced in three
- other subjects during treatment.
- X
- X
- __________
- X
- X 5. That *all* subjects lost fat is significant. In energy
- X deprivation diet studies, some subjects invariably fail
- X to lose weight. In long term diet followup, the
- X standard deviation is two or three times as great as the
- X average weight loss because a large minority gain
- X weight, sometimes a great amount. Without individual
- X data or the standard deviation, one simply cannot judge
- X the true effectiveness of the experimental intervention.
- X Many diet studies suppress this information as it would
- X cause the reader to discount the validity of the claimed
- X results.
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 56 -
- X
- X
- X
- Blood pressure was also reduced, allowing blood pressure
- medication to be discontinued in several.
- X
- In a telephone conversation (June 1992) Dr. Meier reported
- that a third series of clinical trials was underway as part
- of the FDA process to approve the treatment as safe and
- effective. He strongly emphasized how critical TIMING is to
- fat loss; correct dosage given in the wrong rhythm actually
- increases body fat. (According to the Insight article, the
- procedure has been patented.)
- X
- "Our studies also indicate that a cause-effect relationship
- between overfeeding and obesity is oversimplistic and that
- food intake and lipid synthesis may be regulated in a
- concerted fashion by circadian neuroendocrine activities."
- X
- 10.7 TESTOSTERONE TREATMENT
- X
- Men with abdominal obesity have low testosterone values. An
- 8 month study at the Sahigren's Hospital in Goteborg, Sweden
- tested 23 men aged 40-65 years in a double blind experiment
- in restoring testosterone levels to normal. The
- testosterone treated group improved in waist size, blood
- pressure, plasma lipids, fasting glucose, and insulin
- sensitivity. Normalization of testosterone levels reduced
- many of the health warning signs associated with obesity.
- X
- 10.8 BETA3-ADRENOCEPTOR AGONISTS
- X
- Animal studies on several Beta3-agonists show they fulfill
- many of the properties of the ideal anti-obesity drug.
- These compounds produce selective loss of body fat mass with
- a preservation of lean tissue. In addition, the changes in
- body composition are accompanied by favourable metabolic
- changes including improvement in glucose tolerance,
- reduction of hyperinsulinemia and hyperlipidaemia. (S18-3)
- X
- 10.9 SEROTONIN REUPTAKE INHIBITORS
- X
- "The genesis of this project was an invitation to discuss
- anorexiant medications with the house officers in the
- Medical CLinic as Strong Memorial Hospital. The colleague
- who invited me was dismayed that the treatment options used
- in the medical clinic were not helping people lose weight."
- Michael Weintraub, MD "both the medical profession and
- society look with disfavor on obese people and obesity in
- general. ... Obese people are treated negatively in cartoons
- and in literature. Many believe that obese people need only
- to "close their mouths" and be more motivated to lose
- weight. The use of medications to correct a characterologic
- defect is, in the opinion of physicians and the public,
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 57 -
- X
- X
- X
- deemed inappropriate.
- X
- Unfortunately, a lack of understanding of both the natural
- history of obesity and its diversity adds to the perjorative
- view of obese people and of anorexiants. Some health
- professionals are not aware of data concerning mechanisms
- present in the human organism that act to contravene
- pertubations in body weight and that may account for the
- apparent failure of interventions, including medications."
- X
- To provide longer-term data, Weintraub et al developed a 4
- year multimodal program using state-of-the-art behavior
- modification, caloric restriction, and exercise as the
- "placebo" for the entire duration of the four year study.
- Subjects attended nearly 100 visitations with health
- professionals during the study. When reading reports on The
- National Heart, Lung, and Blood Institute funded Multimodal
- Intervention Study, please keep in mind that this "state-
- of-the-art" treatment was the "placebo". (State of the
- diet/exercise/shrink art, that is!) "From the end of the
- second double-blind phase at week 190 through week 210, we
- monitored study participants to see what happened without
- medication but with continuing behavior modification,
- caloric restriction, and exercise therapy. ... One measure
- of the excellence of the ancillary [placebo] therapy in this
- study was that it enabled participants treated with placebo
- to lose just 0.01 kg/week less than participants receiving
- active therapy in the 18 studies that lasted at least 8
- weeks reviewed by Scoville for the FDA."
- X
- 121 subjects, 18 to 60 years old, mean BMI of 33.4 +- 2.2,
- three fourths female, entered the medication phase of the
- study after 6 weeks of behavior mod, diet and exercise. 69
- per cent had been on six or more diets previously.
- X
- Subjects on medication lost about three times the weight as
- those only receiving behavior modification, diet and
- exercise. There was no indication of tolerance or abuse
- potential of the medication. There was no indication that
- use of anorexiant inhibits the learning of behavior
- modification.
- X
- As reported by the New York Times New Service, Dr. Albert
- Stunkard, an obesity researcher at the University of
- Pennsylvania, said he knew of no other study that had
- elicited such a dramatic and sustained weight loss. It
- ``points to the way things are going to go,'' he said.
- X
- The investigators found their patients could not maintain
- their weight loss without the drugs.
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 58 -
- X
- X
- X
- The final 30 weeks of the program assessed what happened
- when all the patients were weaned from the drugs, relying on
- continued diet, exercise and behavior control. They
- gradually regained almost all the weight they had lost,
- despite the continuing program of diet, exercise and
- behavior modification.
- X
- #Some who believe that the essential defect in obesity is
- will power have asserted that the weight regain was from
- subjects' going "off the diet" when medication was
- withdrawn, instead of the diets' poor long term performance.
- A number of facts argue against this assertion:
- X
- X + Fenfluramine's appetite reducing effect wears off
- X within a week. Any increased eating from cessation of
- X the anroectic effect would have occurred much earlier.
- X
- X + Patients were on moderate diets, up to 1800
- X caliores/day for men, 1200 for women. Most of the
- X patients were veterans of a half dozen or more diet
- X attempts. With this amount of metabolic slowdown, the
- X traditional (diet/exercise/behavior mod) part of the
- X program may not have been able to induce much long-term
- X weight loss without benefit of the drugs' lowering of
- X set point.
- X
- X + Lipid profiles, primarily affected by the diet and
- X exercise, confirmed the weight regain was not caused by
- X cheating on the diet.
- X
- When the study was over, and subjects were nearly as fat as
- they were initially, many tried to get the drug combination
- from their private doctors and ran into skepticism over the
- treatment.
- X
- Some experts on weight loss hailed the studies, saying they
- could mark a pronounced shift in the way obesity is studied
- and treated.
- X
- These experts said the results showed obesity could be
- treated the way chronic diseases like high blood pressure or
- arthritis are. In those diseases, drugs must be taken
- indefinitely to keep symptoms in check.
- X
- ``This is a landmark study,'' said Dr. George Blackburn, an
- obesity researcher at New England Deaconess Hospital in
- Boston.
- X
- Study VI of the report discusses individual outcomes. One
- subject did not reach goal weight (120% of ideal) but he was
- able to maintain his weight loss even after medication
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 59 -
- X
- X
- X
- ceased. Some others did reach goal weight but gained it all
- back, or more. Most lost at least some weight but regained
- after medication ceased, despite continuing behavior
- modification, diet and exercise. Some lost little or no
- weight, or gained weight. Many of the failures were due to
- the experimental protocol which did not allow for individual
- adjustments that would have been made in a health care
- setting. Diet evangelists who do not appreciate the deep
- biological diversity of fat people should study this paper
- (and the papers on identical twins) carefully.
- X
- X
- Serotonin-reuptake inhibiting agents include flouxetine
- (Prozac), fenfluramine, and d-fenfluramine (dexfenfluramine,
- dF).
- X
- In France and England, fenfluramine has been used in the
- treatment of human obesity for 25 years. Dexfenfluramine is
- the dextro stereoisomer of fenfluramine, and is a more
- potent antiobesity agent with fewer side effects. "The
- overall incidence of side effects in our studies was lower
- than found in most studies with dl-fenfluramine. Tiredness
- and drowsiness were the most commonly reported unwanted side
- effects of treatment, but occurred as frequently with
- placebo treatment as with dexfenfluramine." (Clinical
- Neuropharmacology Vol 11 Suppl 1 S179)
- X
- X
- The conventional labelling of d-fenfluramine as an appetite
- suppressant is hopelessly oversimplified at best, if not
- downright inaccurate. "According to most authors, tolerance
- to the anorectic effects of d-fenfluramine in rats rapidly
- sets in; food intake is depressed or only 2 to 6 days ...
- However, as long as the drug is administrated, the weight
- deficit persists." (Clinical Neuropharmacology Vol 11 Suppl
- 1 S105)
- X
- #"Following approximately a week of daily ingestion of
- fenfluramine, the body weight of female rats is reduced and
- remains chronically suppressed for as long as treatment is
- continued. This chronic suppression of body weight by
- fenfluramine cannot be explained by the anorectic effects of
- fenfluramine, since food intake returns to normal after
- about a week. Part of this chronic suppression of body
- weight lies in the ability of fenfluramine to enhance the
- thermic effect of food. Fenfluramine ingested by a fasted
- rat causes no change in metabolic rate. However, following
- the ingestion of the meal consisting of mixed nutrients or
- only carbohydrates, the thermic effect of the food is
- significantly greater than that of the meal without
- fenfluramine. A similar observation was observed in humans.
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 60 -
- X
- X
- X
- These observations when combined with the negligible effects
- of dieting as a means of controlling body weight, argue for
- the chronic use of fenfluramine as a therapeutic technique
- to produce sustained weight loss in humans." (Clinical
- Neuropharmacology Vol 11 Suppl 1 S90-2)
- X
- #Is fenfluramine's anorectic effect essential to its
- antiobesity properties? When body weight was reduced in
- rats prior to treatment with fenfluramine, administration of
- the drug was followed by a rapid increase in food intake
- with maintenance of the reduced weight. The reduced body
- weight in fenfluramine-treated rats is defended; when
- animals are force fed to a higher weight and then allows to
- eat ad libitum their food intake drops and body weight
- drops. (Recent Advances in Obesity Research: V 290)
- X
- #Fenfluramine normalizes obese subjects' deficient growth
- hormone (GH) response to arginine. (Hormone Research 1987:
- 27; 190-194)
- X
- Fluoxetine, another serotonin-reuptake inhibiting agent, has
- been shown to improve insulin sensitivity and other
- metabolic actions.
- X
- #Dexfenfluramine is a related drug that increases metabolic
- rate (MR), diet induced thermogenisis (DIT), decreases blood
- pressure, and enhances glucose clearance. Dexfenfluramine
- reduces or prevents weight regain after slimming. The drug
- appears well suited for use in hypertensive or diabetic
- obese patients. (Clinical Neuropharmacology Vol 11 Suppl 1)
- (Progress in Obesity Research 1990) In rat, d-fenfluramine
- improves insulin action of reducing the liver's glucose
- output. (DIABETES Apr 1989)
- X
- The Weintraub study maintains a level of experimental
- design, reportage, disclosure and honesty that distinguishes
- it from most studies of traditional weight loss techniques.
- #It is the longest weight control study of any type. It
- underscores the abject failure of traditional weight loss
- technology to improve the quality of life for most fat
- people.
- X
- Free reprints of this 65 page supplement are available.
- X
- Numerous papers on the antiobesity properties of serotonin-
- reuptake inhibiting agents appeared in Vol 11 Supplement 1
- of Clinical Neuropharmacology (1988).
- X
- X
- X
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 61 -
- X
- X
- X
- 10.10 FAT CELL REMOVAL
- X
- 10.11 Surgery
- X
- Surgery is the only currently available fat reduction
- treatment that has demonstrated long term success in a
- majority of patients.
- X
- Unfortunately, the amount of fat removed by currently
- accepted surgical procedures is too small to be useful for
- mainstream weight reduction purposes.
- X
- A newspaper recently reported an increase in breast size for
- women who had "love handles" removed. It is possible the
- breast size was recovering from the effects of stringent
- dieting undertaken in unsuccessful attempts to spot reduce
- the "love handles".
- X
- A South African study of freely-eating, non-obese
- liposuction patients showed no increase in fat cell size,
- metabolic efficiency, or regional adipose distribution 1 to
- 2 months after surgery.
- X
- Surgical removal of fat in Cushing's Syndrome patients (4F-
- 21) resulted in an increase in lean tissue mass, and no fat
- regain.
- X
- Diabetic patients receiving abdominal liposuction have
- reduced insulin requirements (dose reduced from 20 to 10
- units). (Unpublished data)
- X
- Some efforts are underway to develop surgical procedures to
- significantly normalize fat cell numbers.
- X
- 10.12 Immunological Manipulation
- X
- The Hannah Research Institute in Scotland have developed a
- treatment to reduce adiposity by targeting cytotoxic
- antibodies to fat cells. In early experiments, rat fat cell
- plasma was injected into sheep. The resultant antibodies
- were filtered and introduced into the rats. The treated
- rats lost fat.
- X
- The treated rats also had more lean tissue than untreated
- controls. This suggests fat cells deprive lean tissue of
- nutrients necessary for growth.
- X
- After treatment ended, the rats gained fat in other areas,
- restoring a normal amount of fat. This suggests some higher
- level mechanism prevents adipose mass from falling below
- norms. Normal weight rats were used in these experiments;
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 62 -
- X
- X
- X
- results may be better for obese humans.
- X
- In a telephone conversation in 1991 I was told Hannah's
- research is proceeding very well toward its goal of
- producing leaner animal meat. Human application in the near
- future is unlikely due to risk of malpractice lawsuits.
- X
- Other researchers, using monoclonal antibodies, report
- success in longer term suppression of fat cell numbers.
- (Private conversation, 1992)
- X
- X
- 11. PREDICTIONS
- X
- A portion of the current obesity epidemic will be traced to
- nutritional and hormonal problems during pregnancy and/or
- infancy. Pregnancies with gestational diabetes and other
- problems that previously failed now produce preobese
- children. The introduction of high carbohydrate baby
- formula and sugary baby foods in this century will also be a
- factor. Low fat high carbohydrate weight loss diets applied
- early in life will also be implicated.
- X
- #Within the decade, prescription of energy restriction
- weight loss diets for patients with childhood onset obesity
- will be recognized as a violation of the Hippocratic Oath.
- X
- X
- 12. RECOMMENDATIONS FOR ACTION
- X
- Popular attitudes on obesity are based on the notion that
- obesity is caused by sloth and gluttony. Recent research
- has discredited this stereotype and suggested possibilities
- for effective prevention or treatment in the future.
- X
- X + Truth in Advertising must be enforced on all weight
- X loss claims. Advertising must disclose long term
- X results obtained by typical users, accurately reporting
- X the prevalence of weight regain and overshoot. The
- X Federal Trade Commission is preparing a crackdown on
- X diet companies. (Reuter, May 21 1992) The Clinton
- X administration may be more interventionist in this
- X area.
- X
- X + Diagnostic procedures are needed to identify the 5 per
- X cent of overweight subjects for whom weight loss diets
- X provide long term benefits.
- X
- X + Policies and public education are urgently needed to
- X reduce diet induced adipocyte hyperplasia. (In
- X English: diets make some fatter and we need to do
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 63 -
- X
- X
- X
- X something about it!) This is an area where malpractice
- X and product liability lawyers can do some good. The
- X recent lawsuit settlements by Nutri-System Weight Loss
- X Inc. are a promising start, and a meeting on the
- X subject at a recent Trial Lawyers' convention bodes
- X well for the future. President-elect Clinton's links
- X to trial lawyers and his refusal to criticize
- X malpractice suits may encourage this development.
- X
- X + Effective interventions to correct human obesity must
- X be developed and deployed. Candidates include surgery,
- X immunization to fat cell plasma, CoPP, RU-486,
- X correction of low EGF, testosterone, DHEA and Growth
- X Hormone levels. One hundred million American
- X endomoprphs deserve more than a few dimes' worth of
- X legitimate obesity research.
- X
- X + Doctors should properly diagnose and properly treat the
- X medical conditions of their obese patients instead of
- X insisting on unrealistic weight loss as an alternative
- X or precondition to treatment.
- X
- X + Regulatory interference in the development and
- X deployment of effective new treatments must abate.
- X Public health would be better served if regulators
- X shifted their attention to the abuses of the diet
- X industry.
- X
- X + Mothers should limit carbohydrate and sugar consumption
- X during pregnancy and lactation.
- X
- X + Mothers should breast feed the full recommended time.
- X
- X + Babies should not be fed a high carbohydrate diet.
- X
- "We recognize that the message we have for endocrinologists
- and metabolic specialists is a somber one, difficult to the
- sufferer from obesity. On the other hand, it seems to us
- most consonant with the true state of affairs. Our
- understanding of genetic mechanisms is progressing rapidly
- and the interaction between genetic endowment and early
- environment will be under intensive study in the next
- decade. This is the hopeful side of the problem." (CLINICAL
- REVIEW 28: A Biological Basis for Human Obesity, Journal of
- Clinical Endocrinology and Metabolism, 1991.)
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 64 -
- X
- X
- X
- 13. REQUIRED READING
- X
- Human Obesity: Exploding the Myths The Western Journal of
- Medicine Oct 1990; 153;421-428
- X
- Annals, New York Academy of Sciences, book length issue on
- Human Obesity
- X
- LONG TERM WEIGHT CONTROL:
- The National Heart, Lung, and Blood Institute funded
- multimodal intervention study, Clin Pharmacol Ther, May 1992
- Reprints of the entire supplement are available at no
- charge. Direct requests to:
- Michael Weintraub MD
- Department of Community and Preventive Medicine
- University of Rochester School of Medicine
- PO Box 644
- Rochester NY 14642
- X
- Information on the medications used may be obtained with a
- self addressed stamped envelope mailed to:
- DIET STUDY
- University of Rochester Medical Center
- POB 643
- Rochester NY 14642
- X
- X
- OBESITY AND LEANNESS, Basic Aspects, ISBN 0 86196 0173
- X
- Never Say Diet? article by Ruth Papazian, FDA CONSUMER,
- article downloaded from the Food and Drug Administration
- Bulletin Board. For copies contact the FDA Publications
- Staff at 301-443-3220.
- X
- X
- 14. RECOMMENDED READING
- X
- References such as (4F-21) refer to paper designations in
- the Tokyo Internationl Congress on Obesity abstracted in the
- International Journal of Obesity. Some of these papers
- appear in Progress in Obesity Research 1990 (Proceedings of
- the 6th International Congress on Obesity), John Libbey &
- Sons ISBN 0 86196 274 5
- X
- "Recent Advances in Obesity Research: V" ISBN 0-86196-072-6
- X
- "CLINICAL REVIEW 28: A Biological Basis for Human Obesity",
- Journal of Clinical Endocrinology and Metabolism, 1991.
- X
- "Obesity in Europe 88" ISBN 0-86196-167-6
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- X
- X
- X
- X - 65 -
- X
- X
- X
- International Journal of Obesity (Periodical)
- X
- "Fat Chance" Nova episode broadcast on PBS (1983)
- X
- Annals, New York Academy of Sciences, book length issue on
- Human Obesity
- X
- The Callaway Diet, Bantam non fiction paperback, ISBN-0-
- 553-28708-7 (C Wayne Callaway, M.D. is the former director
- of the Nutrition and Lipid Clinic at The Mayo Clinic, former
- director of the George Washington University Medical Center
- Center for Clinical Nutrition, and has held prominent
- positions with the U.S. Department of Health and Human
- Services, and the National Institutes of Health.)
- X
- "Diet and Health: Implications for reducing chronic disease
- risk"; Committee on Diet and Health Food and Nutrition Board
- Commission on Life Sciences, National Research Council;
- National Academy Council, Washington D.C. 1989.
- X
- Progress in Obesity Research 1990 (Proceedings of the 6th
- International Congress on Obesity), John Libbey & Sons ISBN
- 0 86196 274 5
- X
- "Number and Size of Adipose Tissue Fat Cells in Relation to
- Metabolism in Human Obesity" Page 703, Metabolism, Vol 20 No
- 7 July 1971.
- X
- "Lean Body Mass, Exercise and VLCD", International Journal
- of Obesity (1989), 13 (suppl. 2), 17-25.
- X
- "Super Nutrition for Women", Ann Louise Gittleman, Santa
- Monica Pritikin Longevity Center nutrition director, Bantam
- Books, 1991
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X
- X Adiposity 101
- X
- X
- X
- X
- SHAR_EOF
- echo 'File adiposity.101 is complete' &&
- chmod 0644 adiposity.101 ||
- echo 'restore of adiposity.101 failed'
- Wc_c="`wc -c < 'adiposity.101'`"
- test 150192 -eq "$Wc_c" ||
- echo 'adiposity.101: original size 150192, current size' "$Wc_c"
- rm -f _shar_wnt_.tmp
- fi
- rm -f _shar_seq_.tmp
- echo You have unpacked the last part
- exit 0
-
- --
- Chuck Forsberg WA7KGX ...!tektronix!reed!omen!caf
- Author of YMODEM, ZMODEM, Professional-YAM, ZCOMM, and DSZ
- Omen Technology Inc "The High Reliability Software"
- 17505-V NW Sauvie IS RD Portland OR 97231 503-621-3406
-